The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

People with breathing problems during sleep may have a larger hippocampus, the area of the brain responsible for memory and thinking, according to a study published in the ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating o ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Obstructive sleep apnea (OSA) is a common sleep disorder that affects millions of people around the world. It happens when ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...